The Mexican Journal of Oncology (Gaceta Mexicana de Oncología) is governed according to the following policies:

The journal will have a unique name and design, it will have publication licenses (including Creative Commons), national and international indexing, and ISSN. The journal will have its own secure website.


Scientific manuscripts on oncology, of national and international origin and interest, in Spanish or English, including studies with negative results, that adhere to the international recommendations of good practices will be evaluated.

–    Open access

–    World Health Organization: https://www.who.int/about/policies/publishing/open-access  

–    Plan S: https://www.coalition-s.org/plan_s_principles/

–    International Committee of Medical Journal Editors: https://www.icmje.org/icmje-recommendations.pdf

–    COPE Core practices: https://publicationethics.org/core-practices

–    REWARD: https://www.thelancet.com/campaigns/efficiency/statement

–    EQUATOR (Enhancing the QUAlity and Transparency Of health Research): https://www.equator-network.org/about-us/

– Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. https://www.ismpp.org/gpp-2022#:~:text=GPP%202022%20is%20the%20third,publications%2C%20and%20policies%20and%20procedures


The submitted manuscripts will be evaluated according to their methodological quality, originality, timeliness, relevance, scientific contribution, relevance to the objectives of the Mexican Journal of Oncology (Gaceta Mexicana de Oncología), and adherence to ethical principles. The authorship must follow the principles of COPE (https://publicationethics.org/files/COPE_DD_A4_Authorship_SEPT19_SCREEN_AW.pdf). 


Inclusive language will be promoted. The authors must express their conflicts of interest and they will be responsible for the content of the article.


The publication will be carried out simultaneously in Spanish and English, electronically, in open access, at no cost to authors or readers, and will it be financed by the Mexican Society of Oncology (SMeO). Any external financing will be made through Mexican Society of Oncology (SMeO) and will be independent of the editorial process and decision. The editors will evaluate the relevance of the inclusion of advertisers in the publication.


The evaluation process will be carried out in an agile, systematic way, with quality, transparency, consistency, opportunity, and it will include review by academic peers, blinded for both the author and the reviewer (double blind). Reviewers will receive a written acknowledgment for their voluntary participation.

The publishing house will provide an electronic platform for editorial management, and a repository of published articles. The editors and the publishing house will agree on the annual publishing schedule.


Accepted manuscripts will be published ahead of print. Post-publication discussion will take place through Letters to the Editor. The acceptance of the manuscript for its publication implies the automatic transfer of rights for the publication of the article to Mexican Society of Oncology (SMeO).

Any correction, complaint, appeal, or denunciation will be made through the following email: permanyer@permanyer.com


Authors or publishers may retract in accordance with the COPE Retraction Guidelines https://publicationethics.org/sites/default/files/retraction-guidelines-cope.pdf


The editors, editorial board, editorial committee, peer reviewers and operational staff will have defined responsibilities in accordance with the Operations Manual.


The journal will implement continuous improvement processes on a regular basis, including training activities for the people involved in the editorial process.


The dissemination will be carried out through the electronic site of the journal, emails from members of Mexican Society of Oncology (SMeO) and subscribers to the Toc Alert service and can be carried out through social networks.